Top

Published in:

01-01-2011 | Original paper

Dietary glycemic index, glycemic load, insulin index, fiber and whole-grain intake in relation to risk of prostate cancer

Authors: K. Nimptsch, S. Kenfield, M. K. Jensen, M. J. Stampfer, M. Franz, L. Sampson, J. C. Brand-Miller, W. C. Willett, E. Giovannucci

Published in: Cancer Causes & Control | Issue 1/2011

Abstract

Objective

Insulin may play a role in prostate cancer tumorigenesis. Postprandial blood glucose and insulin responses of foods depend importantly on the carbohydrate quality and quantity, represented by glycemic index (GI), glycemic load (GL), fiber and whole-grain content, but are also influenced by intake of protein and other characteristics. The recently developed insulin index (II) quantifies the postprandial insulin secretion, also taking into account these additional characteristics.

Methods

We investigated the association between dietary GI, GL, II, fiber, and whole grains and risk of total prostate cancer (n = 5,112) and subgroups of prostate cancer as defined by stage or grade in 49,934 male participants of the Health Professionals Follow-up Study. Multivariate adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated using Cox proportional hazards regression.

Results

Dietary GI, GL, II, or fiber was not associated with risk of total or subgroups of prostate cancer. We observed a positive association between dietary intake of whole grains and total prostate cancer (HR highest versus lowest quintile 1.13, 95% CI 1.03–1.24), which was attenuated after restriction to PSA-screened participants (HR 1.03, 95% CI 0.91–1.17).

Conclusions

These results suggest that long-term exposure to a diet with a high insulin response does not affect prostate cancer incidence.

Ferlay J, Bray P, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence mortality and prevalence worldwide. IARC Press, Lyon

Chan JM, Stampfer MJ, Giovannucci EL (1998) What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol 8(4):263–273CrossRefPubMed

Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60(1):91–106CrossRefPubMed

Kaaks R (2004) Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp 262:247–260 (discussion 60–68)

Nandeesha H (2009) Insulin: a novel agent in the pathogenesis of prostate cancer. Int Urol Nephrol 41(2):267–272CrossRefPubMed

Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB et al (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149(7):461–471 (W83–W88)

Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429CrossRefPubMed

Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K et al (2009) Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 101(18):1272–1279CrossRefPubMed

Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ et al (2008) Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 68(1):11–19CrossRefPubMed

10.

Bao J, de Jong V, Atkinson F, Petocz P, Brand-Miller JC (2009) Food insulin index: physiologic basis for predicting insulin demand evoked by composite meals. Am J Clin Nutr 90(4):986–992CrossRefPubMed

11.

Augustin LS, Galeone C, Dal Maso L, Pelucchi C, Ramazzotti V, Jenkins DJ et al (2004) Glycemic index, glycemic load and risk of prostate cancer. Int J Cancer 112(3):446–450CrossRefPubMed

12.

George SM, Mayne ST, Leitzmann MF, Park Y, Schatzkin A, Flood A et al (2009) Dietary glycemic index, glycemic load, and risk of cancer: a prospective cohort study. Am J Epidemiol 169(4):462–472CrossRefPubMed

13.

Pelucchi C, Talamini R, Galeone C, Negri E, Franceschi S, Dal Maso L et al (2004) Fibre intake and prostate cancer risk. Int J Cancer 109(2):278–280CrossRefPubMed

14.

McCann SE, Ambrosone CB, Moysich KB, Brasure J, Marshall JR, Freudenheim JL et al (2005) Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr Cancer 53(1):33–41CrossRefPubMed

15.

Lewis JE, Soler-Vila H, Clark PE, Kresty LA, Allen GO, Hu JJ (2009) Intake of plant foods and associated nutrients in prostate cancer risk. Nutr Cancer 61(2):216–224CrossRefPubMed

16.

Suzuki R, Allen NE, Key TJ, Appleby PN, Tjonneland A, Johnsen NF et al (2009) A prospective analysis of the association between dietary fiber intake and prostate cancer risk in EPIC. Int J Cancer 124(1):245–249CrossRefPubMed

17.

Chatenoud L, Tavani A, La Vecchia C, Jacobs DR Jr, Negri E, Levi F et al (1998) Whole grain food intake and cancer risk. Int J Cancer 77(1):24–28CrossRefPubMed

18.

Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM et al (1981) Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 34(3):362–366PubMed

19.

Foster-Powell K, Holt SH, Brand-Miller JC (2002) International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr 76(1):5–56PubMed

20.

Holt SH, Miller JC, Petocz P (1997) An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods. Am J Clin Nutr 66(5):1264–1276PubMed

21.

Jensen MK, Koh-Banerjee P, Hu FB, Franz M, Sampson L, Gronbaek M et al (2004) Intakes of whole grains, bran, and germ and the risk of coronary heart disease in men. Am J Clin Nutr 80(6):1492–1499PubMed

22.

USDA National Nutrient Database for Standard Reference (2004) Release 17. Agricultural Research Service, Washington, DC

23.

Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC (2005) A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 165(9):1005–1010CrossRefPubMed

24.

Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ (2003) Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 95(16):1240–1244CrossRefPubMed

25.

Platz EA, Leitzmann MF, Michaud DS, Willett WC, Giovannucci E (2003) Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res 63(23):8542–8548PubMed

26.

Salmeron J, Ascherio A, Rimm EB, Colditz GA, Spiegelman D, Jenkins DJ et al (1997) Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 20(4):545–550CrossRefPubMed

27.

Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willett WC (1997) Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 277(6):472–477CrossRefPubMed

28.

Schulze MB, Liu S, Rimm EB, Manson JE, Willett WC, Hu FB (2004) Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr 80(2):348–356PubMed

29.

Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S et al (2007) Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 16(6):1121–1127CrossRefPubMed

30.

Nimptsch K, Platz EA, Pollak MN, Kenfield SA, Stampfer MJ, Willett WC et al (2010) Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993–2004. Int J Cancer

31.

Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M et al (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94(14):1099–1106PubMed

32.

Rohan TE, Howe GR, Burch JD, Jain M (1995) Dietary factors and risk of prostate cancer: a case–control study in Ontario, Canada. Cancer Causes Control 6(2):145–154CrossRefPubMed

33.

Jensen MK, Koh-Banerjee P, Franz M, Sampson L, Gronbaek M, Rimm EB (2006) Whole grains, bran, and germ in relation to homocysteine and markers of glycemic control, lipids, and inflammation 1. Am J Clin Nutr 83(2):275–283PubMed

34.

Liu S, Manson JE, Stampfer MJ, Holmes MD, Hu FB, Hankinson SE et al (2001) Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. Am J Clin Nutr 73(3):560–566PubMed

35.

Wu T, Giovannucci E, Pischon T, Hankinson SE, Ma J, Rifai N et al (2004) Fructose, glycemic load, and quantity and quality of carbohydrate in relation to plasma C-peptide concentrations in US women. Am J Clin Nutr 80(4):1043–1049PubMed

36.

Fung TT, Hu FB, Pereira MA, Liu S, Stampfer MJ, Colditz GA et al (2002) Whole-grain intake and the risk of type 2 diabetes: a prospective study in men. Am J Clin Nutr 76(3):535–540PubMed

37.

Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915–928CrossRefPubMed

38.

Hsing AW, Gao YT, Chua S Jr, Deng J, Stanczyk FZ (2003) Insulin resistance and prostate cancer risk. J Natl Cancer Inst 95(1):67–71CrossRefPubMed

39.

Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH et al (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92(23):1910–1917CrossRefPubMed

40.

Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047CrossRefPubMed

41.

Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B et al (2007) Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 120(12):2678–2686CrossRefPubMed

42.

Gnagnarella P, Gandini S, La Vecchia C, Maisonneuve P (2008) Glycemic index, glycemic load, and cancer risk: a meta-analysis. Am J Clin Nutr 87(6):1793–1801PubMed

Title: Dietary glycemic index, glycemic load, insulin index, fiber and whole-grain intake in relation to risk of prostate cancer
Authors: K. Nimptsch
S. Kenfield
M. K. Jensen
M. J. Stampfer
M. Franz
L. Sampson
J. C. Brand-Miller
W. C. Willett
E. Giovannucci
Publication date: 01-01-2011
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 1/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9671-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Complementary approaches to assessing risk factors for interval breast cancer

Secondhand smoke exposure in bars and restaurants in Guatemala City: before and after smoking ban evaluation

The roles of ultraviolet-B irradiance, vitamin D, apolipoprotein E ε4, and diet in the risk of prostate cancer

Dietary methyl donors, methyl metabolizing enzymes, and epigenetic regulators: diet–gene interactions and promoter CpG island hypermethylation in colorectal cancer

Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven case–control studies in the International Lung Cancer Consortium (ILCCO)

Reduction in arsenic intake from water has different impacts on lung cancer and bladder cancer in an arseniasis endemic area in Taiwan

Keynote webinar | Spotlight on antibody–drug conjugates in cancer